US Study Reveals CP-GEP's Profound Impact on Stratifying Melanoma Patients for Long-Term Survival
ROTTERDAM, Netherlands and SAN DIEGO, Nov. 6, 2023 . SkylineDx, an innovative molecular diagnostics company, is pleased to announce the forthcoming presentation of an impactful poster by Dr M.E. Egger at the upcoming Society for Melanoma Research... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 7, 2023 Category: Pharmaceuticals Source Type: clinical trials
Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response
Conditions: Melanoma Interventions: Drug: Nivolumab Sponsors: Erasmus Medical Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo ® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Conditions: Advanced Melanoma Interventions: Drug: BCD-263; Drug: Opdivo Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo ® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Conditions: Advanced Melanoma Interventions: Drug: BCD-263; Drug: Opdivo Sponsors: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Conditions: Advanced Melanoma Interventions: Biological: IMC-F106C; Biological: Nivolumab; Biological: Nivolumab + Relatlimab Sponsors: Immunocore Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
Conditions: Melanoma Interventions: Drug: relatlimab+nivolumab; Drug: relatlimab+nivolumab+rHuPH20; Drug: nivolumab; Drug: nivolumab+rHuPH20 Sponsors: Bristol-Myers Squibb Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Conditions: Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma Interventions: Biological: Pembrolizumab co-formulated with hyaluronidase; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Investigating Participation Patterns Among Stage IV Melanoma Patients
Conditions: Stage IV Melanoma Sponsors: Power Life Sciences Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
A Study of IBI363 in Subjects With Advanced Melanoma
Conditions: Melanoma Interventions: Biological: IBI363 Sponsors: Innovent Biologics (Suzhou) Co. Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy
Conditions: Skin Cancer; Melanoma Interventions: Other: AI assistance Sponsors: Karolinska University Hospital; Karolinska Institutet; Medical University of Vienna; Stockholm School of Economics Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
Psychoeducation for Uveal Melanoma
Conditions: Uveal Melanoma Interventions: Behavioral: Education for Intervention; Behavioral: Best Practice Sponsors: Jonsson Comprehensive Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Lung Carcinoma; Locally Advanced Malignant Solid Neoplasm; Locally Advanced Melanoma; Metastatic Lung Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Melanoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 Interventions: Procedure: Biospecimen Collection; Other: Electronic Health Record Review Sponsors: Mayo Clinic; National Cancer Institute (NCI) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
Conditions: Uveal Melanoma Interventions: Other: Questionnaires and interviews Sponsors: Institut Curie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 9, 2023 Category: Research Source Type: clinical trials
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
Conditions: Uveal Melanoma Interventions: Drug: Tebentafusp Sponsors: Diwakar Davar; Immunocore Ltd Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 6, 2023 Category: Research Source Type: clinical trials
